How Oral Liquid Bottle Manufacturers Produce Safe and Sterile Pharmaceutical Packaging Containers

Introduction

Oral liquid medications—including syrups, suspensions, solutions, and drops—represent a significant segment of the global pharmaceutical market. The containers that hold these products, commonly known as oral liquid bottles, must meet stringent safety and sterility requirements to protect patient health. Unlike injectable vials that require terminal sterility, oral liquid bottles are typically not terminally sterilized after filling; instead, they must be manufactured with extremely low bioburden and be free from pathogenic microorganisms. However, the manufacturing process itself involves multiple critical steps to ensure that the container does not introduce contaminants into the drug product.

The global pharmaceutical glass packaging market was valued at approximately USD 21.5 billion in 2025 and is projected to grow at a CAGR of 6.8% through 2032, driven by increasing demand for oral liquid formulations, especially in pediatric and geriatric care. As a professional supplier of high-quality pharmaceutical packaging materials, PharGlass specializes in the production of oral liquid bottles made from borosilicate glass tubes, along with rubber stoppers, aluminum plastic caps, and other primary packaging components. With OEM/ODM support, strict quality control systems, and reliable global delivery, PharGlass ensures that every bottle leaving our facility meets the highest standards of safety and cleanliness.

Raw Material Selection and Pretreatment: The Foundation of Chemical Stability

The production of safe oral liquid bottles begins long before the glass is melted. The primary raw material is pharmaceutical‑grade glass tubing, typically complying with low‑borosilicate or medium‑borosilicate standards according to national and international pharmacopoeias (e.g., USP <660>, EP 3.2.1). The chemical composition of the glass directly determines its hydrolytic resistance and overall chemical stability. Inadequate chemical stability can lead to the leaching of alkali ions (e.g., sodium, potassium) and other undesirable substances into the oral liquid drug product during long‑term storage, potentially altering pH, causing precipitation, or even generating toxic leachables.

Em PharGlass, each batch of incoming glass tubing undergoes rigorous incoming inspection, including:

• Coefficient of thermal expansion (CTE): Ensuring dimensional compatibility with downstream processing equipment.
• Hydrolytic resistance (tested per USP <660> or ISO 719): Measuring the amount of alkali released from the glass surface under controlled conditions. Low‑borosilicate glass typically achieves Class HGA1 (highest resistance).
• Acid resistance (ISO 1776) and surface defect inspection: Detecting any pre‑existing cracks or inclusions that could become failure points.

Only glass tubing that meets these specifications is released for production. This strict material control ensures that the finished oral liquid bottle will not compromise the drug product’s stability or safety over its intended shelf life.

Forming and Primary Cleaning: Molding the Bottle Under Controlled Conditions

Once raw glass tubing is approved, it enters the forming stage. The glass tube is fed into a high‑temperature forming machine (typically a rotary or linear vial/bottle forming line), where it is heated in a furnace to approximately 800–1,200°C until soft. Using either blow‑forming or drawing processes, the softened tube is shaped into the final bottle geometry—including the neck finish, body contours, and any design features such as graduation marks or grip ridges.

During this stage, two factors are critical for maintaining cleanliness:

Mold Cleanliness

The molds (or forming tools) that contact the softened glass must be exceptionally clean. Any microscopic organic residue or particulate on the mold surface can become embedded in the external glass surface at high temperatures, creating a permanent source of contamination. At PharGlass, molds undergo regular deep cleaning using methods such as plasma cleaning, ultrasonic degreasing, or high‑temperature baking to remove all organic residues and metal oxides.

Temperature Profile Control

The heating and cooling rates must be precisely controlled. Rapid or uneven cooling can induce residual stresses that weaken the bottle or cause micro‑cracks, which later become sites for microbial attachment or particle shedding. Controlled annealing (gradual cooling) relieves these stresses and improves overall mechanical integrity.

Immediately after forming, hot bottles are subjected to a primary dust removal step using clean compressed air (filtered to remove oil and particulates) to blow off any loose particles generated during the forming process. This initial cleaning reduces the burden on subsequent washing stages.

Multi‑Stage Cleaning: Removing Chemical and Particulate Contaminants

After forming and annealing, the bottles are still not sterile. They carry residues from the forming process (e.g., mold release agents, airborne dust, and handling contaminants). A robust cleaning process is essential to achieve a low bioburden state prior to sterilization. Typical cleaning sequences for oral liquid bottles include several interrelated stages:

1. Alkaline Wash

An alkaline cleaning solution (e.g., sodium hydroxide or a formulated detergent) is circulated through or sprayed onto the bottles. This step saponifies and emulsifies organic residues such as oils, greases, and proteinaceous material. The solution concentration, temperature (typically 50–80°C), and contact time are validated to ensure consistent removal.

2. Acid Wash

Following the alkaline wash, an acidic solution (e.g., dilute hydrochloric or citric acid) is applied. This neutralizes any remaining alkaline residues and dissolves certain metal ions (e.g., iron, aluminum) that may have deposited on the glass surface from process water or equipment.

3. Ultrasonic Cleaning

Ultrasonic cleaning is highly effective at dislodging particles embedded in microscopic pits or crevices on the glass surface. High‑frequency sound waves (typically 20–40 kHz) create cavitation bubbles that implode near the glass surface, generating intense localized energy that lifts and removes sub‑micron particles. This step is especially important for oral liquid bottles intended for suspensions or solutions where visible particles are unacceptable.

4. Rinsing with Purified Water

Multiple rinses with purified water (or water for injection, WFI, for higher‑grade products) remove all traces of cleaning agents and dislodged particles. The quality of rinse water is continuously monitored for conductivity, total organic carbon (TOC), and microbial count.

The sequence, concentration, temperature, and duration of each cleaning step must be validated through worst‑case challenge studies, typically using artificially soiled bottles and measuring residual contaminants by methods such as total organic carbon analysis, conductivity, or visual inspection under magnification. At PharGlass, we maintain validated cleaning protocols that are re‑validated annually or after any significant process change.

Dry Heat Sterilization and Depyrogenation: Achieving Sterility and Endotoxin Reduction

After cleaning, the bottles are still not sterile—they may contain viable microorganisms, albeit at very low levels. The next critical step is thermal sterilization, typically performed using a tunnel‑type dry heat sterilizer (hot air tunnel). The bottles pass through three zones on a conveyor belt: pre‑heating, heating (sterilization/depyrogenation), and cooling.

Sterilization Conditions

To achieve sterility, the bottles are exposed to dry heat at temperatures typically ≥300°C (often 320–350°C) for a defined residence time, e.g., 5–10 minutes. Dry heat sterilization follows first‑order kinetics, and the process is designed to achieve a Nível de garantia de esterilidade (SAL) of 10⁻⁶ for the container interior. However, it is important to note that oral liquid bottles are not required to meet the same SAL as parenteral containers; nevertheless, manufacturers aim for the lowest possible bioburden, with no pathogenic microorganisms (e.g., Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans) detected.

Depyrogenation – Removal of Endotoxins

Beyond sterilization, dry heat tunnels also achieve depyrogenation—the inactivation or removal of bacterial endotoxins (lipopolysaccharides from Gram‑negative bacteria). Endotoxins are heat‑stable and can cause febrile reactions if introduced into the bloodstream. While oral administration typically does not result in endotoxin absorption, many oral liquid bottles are manufactured to parenteral standards as a precautionary measure for products that may come into contact with compromised mucosa or for global regulatory alignment.

The depyrogenation process requires higher temperatures (≥250°C) and longer exposure to achieve a 3‑log reduction in endotoxin activity, as verified by the Limulus Amebocyte Lysate (LAL) test. Most dry heat tunnels are validated to ensure that the coolest bottle in the load (the “cold spot”) receives the required lethality (Fh value, e.g., Fh ≥ 45 minutes at 250°C reference).

At PharGlass, we map temperature profiles across the sterilizer regularly and place biological indicators (e.g., Geobacillus stearothermophilus spores for sterilization) and endotoxin indicators (e.g., E. coli LPS) during validation runs to confirm performance.

Container Closure Integrity: The Final Physical Barrier

Sterilized oral liquid bottles are immediately capped to prevent recontamination. The closure system—typically an aluminum‑plastic combination cap (flip‑off cap) or a rubber stopper with an aluminum overseal—must form a hermetic seal with the bottle’s neck finish. The sealing mechanism is critical because even if the bottle interior is sterile, a compromised seal allows ingress of airborne microorganisms and moisture during storage and transport.

Manufacturers employ several validated Container Closure Integrity Tests (CCIT) to verify seal quality on each batch:

• Negative pressure (vacuum) leak test: Bottles are submerged in a dye solution (e.g., 0.1% methylene blue) under vacuum. If a leak exists, air escapes during vacuum and dye is drawn into the bottle upon pressure restoration. Visible dye inside indicates failure.
• Dye ingress test (color water penetration): A simpler version where bottles are immersed in colored water under pressure or vacuum cycles.
• Headspace gas analysis (for larger batches): Using laser‑based or mass spectrometry methods to detect gas leakage—more sensitive but less common for oral liquids.
• Torque testing (for screw caps): Ensuring consistent application force to achieve repeatable seal compression.

At PharGlass, every batch undergoes CCIT sampling according to an AQL (Acceptable Quality Limit) plan, and any batch showing seal failures is rejected or re‑inspected. Additionally, we validate the sealing machine parameters (cap placement force, crimping pressure) daily.

Environmental Controls and Cleanroom Standards

The entire manufacturing process—especially from cleaning through capping—must take place within a controlled environment to minimize airborne particle and microbial contamination. PharGlass operates in cleanrooms that meet international standards such as ISO 14644-1.

Typical cleanroom classifications for oral liquid bottle production:

• Forming and initial cleaning: ISO 8 (Class 100,000) or better.
• Post‑wash handling and dry heat loading: ISO 7 (Class 10,000).
• Sterilized bottle handling, capping, and packaging: ISO 5 (Class 100) or better, often using laminar airflow hoods or isolators.

Key environmental control measures include:

• HEPA‑filtered air: Supplied through ceiling diffusers, with 99.97% efficiency for 0.3 µm particles.
• Positive pressure: The cleanroom is maintained at higher pressure than adjacent areas to prevent infiltration of unfiltered air.
• Personnel gowning: Operators wear sterile or clean‑room specific gowns (coveralls, gloves, masks, goggles) and follow strict entry/exit procedures including air showers and hand sanitization.
• Surface and air monitoring: Regular settling plates, active air samplers, and contact plates for surfaces to quantify viable and non‑viable particle counts.

Environmental data is trended to detect any deviation before it leads to product contamination. At PharGlass, we perform quarterly cleanroom recertification and daily routine monitoring to maintain compliance with regulatory expectations (e.g., EU GMP Annex 1, which sets stringent limits for even non‑sterile pharmaceutical packaging).

Why Pharmaceutical Companies Still Re‑wash or Re‑sterilize – Understanding Sterility Assurance Levels

A frequently asked question is: If the oral liquid bottle manufacturer has already washed and sterilized the containers, why do many pharmaceutical companies re‑wash or re‑sterilize them before filling? The answer lies in the conceptual difference between “low bioburden” e “sterile assurance” .

Pharmaceutical packaging manufacturers like PharGlass deliver products that have extremely low initial bioburden, are free from specified pathogens, and have been dry‑heat treated to inactivate most microorganisms and endotoxins. However, the industry standard for terminally sterilized drug products (especially parenterals) is a Sterility Assurance Level (SAL) of 10⁻⁶—i.e., no more than one viable microorganism per one million units. Achieving such a high probability of sterility typically requires terminal sterilization of the filled product (e.g., autoclaving the filled oral liquid bottle) or aseptic filling with online sterilization just before filling.

Moreover, transportation, handling, and storage after the original sterilization step can potentially recontaminate the bottle exterior or interior if packaging is damaged. Consequently, many pharmaceutical companies prefer to receive non‑sterile but low‑bioburden bottles and perform their own validated washing and sterilization (e.g., a tunnel washer/dry heat sterilizer integrated with their filling line). This gives them complete control over the chain of sterility from container to sealed drug product.

At PharGlass, we offer both sterile‑ready (gamma or dry heat sterilized, double‑bagged) and non‑sterile (low bioburden, cleaned) options, allowing customers to choose based on their filling line configuration and regulatory strategy.

Process Validation and Quality Control

Safety and sterility cannot be tested into a product—they must be built into the process. Therefore, every stage described above is subject to rigorous process validation and ongoing in‑process control.

Key validation activities include:

• Cleaning validation: Demonstrating that the multi‑step washing process consistently removes soil, particles, and chemical residues to predetermined acceptance criteria.
• Dry heat sterilizer validation: Temperature mapping, heat penetration studies, biological indicator (BI) challenges (e.g., Geobacillus stearothermophilus with D‑value > 1.5 minutes at 121°C equivalent), and endotoxin indicator (EI) challenges for depyrogenation.
• CCIT method validation: Establishing sensitivity, specificity, and reproducibility using positive controls (e.g., micro‑drilled defects of 5–10 µm).
• Environmental monitoring trend analysis: Setting action and alert limits for particles and microorganisms.

Routine quality control (QC) testing on finished products includes:

• Visual inspection (illuminated against a black/white background) for particles, cracks, or defects.
• Dimensional inspection (neck finish dimensions, bottle height, wall thickness).
• Chemical resistance testing (spot‑checking hydrolytic class).
• Bioburden testing (for non‑sterile products) and sterility testing (for sterile‑claimed products per USP <71> or EP 2.6.1).

All test results are documented in batch records and retained for regulatory inspection. At PharGlass, we maintain an ISO 15378 certified quality management system (primary packaging materials for medicinal products), ensuring full traceability from raw material supplier to finished product shipment.

PharGlass: Your Trusted Partner for Oral Liquid Bottles

Em PharGlass, we take pride in our comprehensive approach to safety and sterility. Our oral liquid bottles are manufactured from pharmacopoeial‑grade glass tubing, processed through validated cleaning, dry heat sterilization, and capping lines, and tested for container closure integrity and environmental compliance. With OEM/ODM capabilities, we can customize bottle shapes, neck finishes, graduation marks, and closure systems to meet your specific drug product requirements.

Whether you need low‑bioburden bottles for your own terminal sterilization process or ready‑to‑fill sterile bottles for aseptic lines, PharGlass delivers with reliable lead times, rigorous documentation, and global shipping expertise. Our commitment to quality is backed by continuous investment in process validation, cleanroom infrastructure, and personnel training.

Conclusão

The production of safe, sterile oral liquid bottles is a systematic engineering challenge that integrates material science, microbiology, mechanical design, and environmental control. From incoming glass tube inspection, mold cleanliness, and multi‑stage cleaning (alkaline, acid, ultrasonic) to dry heat sterilization/depyrogenation, container closure integrity testing, and cleanroom management—each step directly influences the final safety of the pharmaceutical packaging.

Importantly, manufacturers like PharGlass provide a critical foundation of low bioburden and absence of pathogens, but the ultimate sterility of the filled drug product often requires terminal sterilization or aseptic processing at the pharmaceutical company’s facility. Understanding this distinction allows both packaging suppliers and drug manufacturers to design robust contamination control strategies.

For pharmaceutical companies seeking a reliable partner for oral liquid bottles, rubber stoppers, aluminum caps, or complete packaging systems, PharGlass offers the technical expertise, quality assurance, and supply chain reliability required for global markets. Contact us today to discuss your project requirements.